Compare Dow Inc (DOW) vs Summit Therapeutics Inc (SMMT) Price & Performance

DOW trades at $28.42, up 2.34% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported negative net income of -$2.62B in 2025, though it has beaten EPS estimates in recent quarters. Revenue declined to $39.97B in 2025 from $56.9B in 2022, while cash flow from operations dropped significantly. Analyst consensus is a 'Hold' with a $34.22 price target, indicating potential upside from current levels.

The outlook for DOW is cautious due to profitability challenges and declining revenue, offset by positive earnings surprises and a dividend payment. Key risks include margin pressures and high debt levels, while opportunities lie in cost management and market recovery. Investors should weigh the stock's valuation against its financial health and sector headwinds.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.